Trials / Completed
CompletedNCT00394823
VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients
A Randomized, Open-label, Multicentric Parallel Group Study to Assess the Impact of Supportive Measures on the Drug Adherence of Patients With Essential Hypertension Treated With Valsartan or Valsartan Plus HCTZ for 34 Weeks With or Without Respective Measures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 206 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the impact of supportive measures on the drug adherence of patients with essential hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Set of supportive tools/measures vs. standard care |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2006-11-01
- Last updated
- 2017-05-18
Locations
2 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00394823. Inclusion in this directory is not an endorsement.